Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles

Virology

Volumn 220, Issue 1, 1996, Pages 128-140

  Wagner, Ralf ^a   Deml, Ludwig ^a   Schirmbeck, Reinhold ^b   Niedrig, Mathias ^c   Reimann, Jörg ^b   Wolf, Hans ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CHIMERA; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; VIRUS EXPRESSION; VIRUS PARTICLE;

EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 0029897413     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0293     Document Type: Article

References (64)

1. Almond, N., Kent, K., Cranage, M., Rud, E., Clarke, B., and Stott, E. J. (1995). Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells [see comments]. Lancet 345, 1342-1344.
2. Amadori, A., De Silvestro, G., Zamarchi, R., Veronese, M. L., Mazza, M. R., Schiavo, G., Panozzo, M., De Rossi, A., Ometto, L., Mous, J., et al. (1992). CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients. J. Immunol. 148, 2709-2716.
3. Bergmann, C., Stohlmann, S. A., and McMillan, M. (1993). An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein. Eur. J. Immunol. 23, 2777-2781.
4. Bryson, Y. J., Pang, S., Wei, L. S., Dickover, R., Diagne, A., and Chen, I. S. (1995). Clearance of HIVinfection in a perinatally infected infant [see comments]. N. Engl. J. Med. 332, 833-838.
5. Cao, Y., Qin, L., Zhang, L., Safrit, J., and Ho, D. D. (1995). Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection [see comments]. N. Engl. J. Med. 332, 201-208.
6. Cox, W. I., Tartaglia, J., and Paoletti, E. (1993). Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195, 845-850.
7. Daniel, M. D., Kirchhoff, F., Czajak, S. C., Sehgal, P. K., and Desrosiers, R. C. (1992). Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene [see comments]. Science 258, 1938-1941.
8. Golding, H., Shearer, G. M., Hillman, K., Lucas, P., Manischewitz, J., Zajac, R. A., Clerici, M., Gress, R. E., Boswell, R. N., and Golding, B. (1989). Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J. Clin. Invest. 83, 1430-1435.
9. Gotch, F. M., Nixon, D. F., Alp, N., McMichael, A. J., and Borysiewicz, L. K. (1990). High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int. Immunol. 2, 707-712.
10. Gottlinger, H. G., Sodroski, J. G., and Haseltine, W. A. (1989). Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86, 5781-5785.
11. Gottlinger, H. G., Dorfman, T., Sodroski, J. G., and Haseltine, W. A. (1991). Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc. Natl. Acad. Sci. USA 88, 3195-3199.
12. Gottlinger, H. G., Dorfman, T., Cohen, E. A., and Haseltine, W. A. (1993). Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. USA 90, 7381-7385.
13. Griffiths, J. C., Harris, S. J., Layton, G. T., Berrie, E. L., French, T. J., Burns, N. R., Adams, S. E., and Kingsman, A. J. (1993). Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol. 67, 3191-3198.
14. Heeg, K., Kuon, W., and Wagner, H. (1991). Vaccination of class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: Immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur. J. Immunol. 21, 1523-1527.
15. Huang, Y., Zhang, L., and Ho, D. D. (1995). Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 69, 93-100.
16. Jones, T. A., Blaug, G., Hansen, M., and Barklis, E. (1990). Assembly of gag-beta-galactosidase proteins into retrovirus particles. J. Virol. 64, 2265-2279.
17. Kondo, E., Mammano, F., Cohen, E. A., and Gottlinger, H. G. (1995). The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J. Virol. 69, 2759-2764.
18. Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C., and Ho, D. D. (1994). Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655.
19. Koup, R. A., and Ho, D. D. (1994). Shutting down HIV [news; comment]. Nature 370, 416.
20. Kutubuddin, M., Simons, J., and Chow, M. (1992). Poliovirus-specific major histocompatibility complex class I-restricted cytolytic T-cell epitopes in mice localize to neutralizing antigenic regions. J. Virol. 66, 5967-5974.
21. Lasky, L. A., Nakamura, G., Smith, D. H., Fennie, C., Shimasaki, C., Patzer, E., Berman, P., Gregory, T., and Capon, D. J. (1987). Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50, 975-985.
22. Layton, G. T., Harris, S. J., Gearing, A. J., Hill Perkins, M., Cole, J. S., Griffiths, J. C., Burns, N. R., Kingsman, A. J., and Adams, S. E. (1993). Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J. Immunol. 151, 1097-1107.
23. Lu, S., Santoro, J. C., Fuller, D. H., Haynes, J. R., and Robinson, H. L. (1995). Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 209, 147-154.
24. Luo, L., Li, Y., Cannon, P. M., Kim, S., and Kang, C. Y. (1992). Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc. Natl. Acad. Sci. USA 89, 10527-10531.
25. Mammano, F., Ohagen, A., Hoglund, S., and Gottlinger, H. G. (1994). Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J. Virol. 68, 4927-4936.
26. Monaco, J. J. (1992). Major histocompatibility complex-linked transport proteins and antigen processing. Immunol. Res. 11, 125-132.
27. Nair, S., Zhou, X., Huang, L., and Rouse, B. T. (1992). Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. J. Immunol. Methods 152, 237-243.
28. Newman, M. J., Wu, J. Y., Gardner, B. H., Munroe, K. J., Leombruno, D., Recchia, J., Kensil, C. R, and Coughlin, R. T. (1992). Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 148, 2357-2362.
29. Niedrig, M., Gelderblom, H. R., Pauli, G., Marz, J., Bickhard, H., Wolf, H., and Modrow, S. (1994). Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides. J. Gen. Virol. 75, 1469-1474.
30. Nixon, D. F., Townsend, A. R., Elvin, J. G., Rizza, C. R., Gallwey, J., and McMichael, A. J. (1988). HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 336, 484-487.
31. Osterrieder, N., Wagner, R., Brandmuller, C., Schmidt, P., Wolf, H., and Kaaden, O. R. (1995). Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology 208, 500-510.
32. Parent, L. J., Bennett, R. P., Craven, R. C., Nelle, T. D., Krishna, N. K., Bowzard, J. B., Wilson, C. B., Puffer, B. A., Montelaro, R. C., and Wills, J. W. (1995). Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J. Virol. 69, 5455-5460.
33. Patzer, E. J., Nakamura, G. R., and Yaffe, A. (1984). Intracellular transport and secretion of hepatitis B surface antigen in mammalian cells. J. Virol. 51, 346-353.
34. Paul-WE, (1995). Can the immune response control HIV infection? Cell 82, 177-182.
35. Phillips, R. E., Rowland Jones, S., Nixon, D. F., Gotch, F. M., Edwards, J. P., Ogunlesi, A. O., Elvin, J. G., Rothbard, J. A., Bangham, C. R., Rizza, C. R., et al. (1991). Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition [see comments]. Nature 354, 453-459.
36. Pinto, L., Sullivan, J., Berzofski, J., Clerici, M., Kessler, H., Landay, A., and Shearer, G. (1995). Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Invest., in press.
37. Reddy, R., Zhou, F., Nair, S., Huang, L., and Rouse, B. T. (1992). In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol. 148, 1585-1589.
38. Riddell, S. R., Rabin, M., Geballe, A. P., Britt, W. J., and Greenberg, P. D. (1991). Class I MHC-restricted cytotoxic T lymhocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 146, 2795-2804.
39. Robinson, W. E., Jr., Montefiori, D. C., Gillespie, D. H., and Mitchell, W. M. (1989a). Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J. Acquir. Immune Defic. Syndr. 2, 33-42.
40. Robinson, W. E., Jr., Montefiori, D. C., Mitchell, W. M., Prince, A. M., Alter, H. J., Dreesman, G. R., and Eichberg, J. W. (1989b). Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc. Natl. Acad. Sci. USA 86, 4710-4714.
41. Rowland-Jones, S., Sutton, J., Arijoshi, K., Dong, T., Gotch, F., Mo-Adam, S., Whitby, D., Sabally, S., Allimore, A., Corrah, T., Taciguchi, M., Schultz, T., McMichal, A., and Whittle, H. (1995). HIV-specific cytotoxic T-cells in HIV exposed but uninfected Gambian woman. Nature Med. 1, 59-64.
42. Schirmbeck, R., Zerrahn, J., Kuhrober, A., Kury, E., Deppert, W., and Reimann, J. (1992). Immunization with soluble simian virus 40 large T antigen induces a specific response of CD3+ CD4- CD8+ cytotoxic T lymphocytes in mice. Eur. J. Immunol. 22, 759-766.
43. Schirmbeck, R., Melber, K., Kuhrober, A., Janowicz, Z. A., and Reimann, J. (1994). Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J. Immunol. 152, 1110-1119.
44. Schirmbeck, R., Deml, L., Melber, K., Wolf, H., Wagner, R., and Reimann, J. (1995a). Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine 13, 857-865.
45. Schirmbeck, R., Melber, K., and Reimann, J. (1995b). Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur. J. Immunol. 25, 1063-1070.
46. Siliciano, R. F., Lawton, T., Knall, C., Karr, R. W., Berman, P., Gregory, T., and Reinherz, E. L. (1988). Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell 54, 561-575.
47. Smith, G. E., Ju, G., Ericson, B. L., Moschera, J., Lahm, H. W., Chizzonite, R., and Summers, M. D. (1985). Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector. Proc. Natl. Acad. Sci. USA 82, 8404-8408.
48. Takahashi, H., Cohen, J., Hosmalin, A., Cease, K. B., Houghten, R., Cornette, J. L., DeLisi, C., Moss, B., Germain, R. N., and Berzofsky, J. A. (1988). An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85, 3105-3109.
49. Takeda, A., Robinson, J. E., Ho, D. D., Debouck, C., Haigwood, N. L., and Ennis, F. A. (1992). Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120. J. Clin. Invest. 89, 1952-1957.
50. Townsend, A., and Bodmer, H. (1989). Antigen recognition by class I-restricted T lymphocytes. Annu. Rev. Immunol. 7, 601-624.
51. Tyler, D. S., Nastala, C. L., Stanley, S. D., Matthews, T. J., Lyerly, H. K., Bolognesi, D. P., and Weinhold, K. J. (1989). GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. J. Immunol. 142, 1177-1182.
52. von Poblotzki, A., Wagner, R., Niedrig, M., Wanner, G., Wolf, H., and Modrow, S. (1993). Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation. Virology 193, 981-985.
53. Wagner, R., Fliessbach, H., Wanner, G., Motz, M., Niedrig, M., Deby, G., von Brunn, A., and Wolf, H. (1992a). Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch. Virol. 127, 117-137.
54. Wagner, R., Modrow, S., Boltz, T., Riessbach, H., Niedrig, M., von Brunn, A., and Wolf, H. (1992b). Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3. Arch. Virol. 127, 139-152.
55. Wagner, R., Boltz, T., Deml, L., Modrow, S., and Wolf, H. (1993). Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. J. Gen. Virol. 74, 1261-1269.
56. Wagner, R., Deml, L., Fliessbach, H., Wanner, G., and Wolf, H. (1994). Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology 200, 162-175.
57. Wagner, R., Deml, L., Fitzon, T., and Wolf, H. (1995). In "Vaccines 95: Molecular Approaches to the Control of Infectious Diseases" (R. M. Chanock, F. Brown, H. S. Ginsberg, and E. Norrby, Eds.), pp. 347-356. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
58. Weinhold, K. J., Lyerly, H. K., Stanley, S. D., Austin, A. A., Matthews, T. J., and Bolognesi, D. P. (1989). HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol. 142, 3091-3097.
59. Weldon, R. A., Jr., Erdie, C. R., Oliver, M. G., and Wills, J. W. (1990). Incorporation of chimeric gag protein into retroviral particles. J. Virol. 64, 4169-4179.
60. Wolf, H., Modrow, S., and Wagner, R. (1994). "Retroviruses of Human AIDS and Related Animal Diseases" (R. Odile, Ed.), pp. 299-307. Colloque Des Cent Gardes, Marnes-La-Coquette, Paris, France.
61. Wolf, H., Modrow, S., Soutschek, E., Motz, M., Grunow, R., and Döbl, H. (1990). Production, mapping and biological characterization of monoclonal antibodies to the core protein (p24) of the human immunodeficiency virus type 1. AIFO 1, 24-29.
62. Wraith, D. C., Vessey, A. E., and Askonas, B. A. (1987). Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 68, 433-440.
63. Yewdell, J. W., and Bennink, J. R. (1992). Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv. Immunol. 52, 1-123.
64. Young, J. A. (1988). HIV and HLA similarity [letter]. Nature 333, 215.